Posters
Comparison of macular thickness and ganglion cell complex (GCC) thickness in diabetic and glaucoma patients using spectral domain optical coherence tomography
Poster Details
First Author: D.Shah INDIA
Co Author(s): R. Dhamankar S. Haldipurkar V. Shetty Z. Khatib S. Tanwar P. Sankhe
Abstract Details
Purpose:
To study the individual and combined effects of diabetes and glaucoma on macular thickness and ganglion cell complex thickness.
Setting:
Laxmi Eye Institute, tertiary eye care centre, Panvel, Navi Mumbai
Methods:
Spectral Domain Optical Coherence Tomography (SD-OCT) RTVue-100 was used to measure the study parameters. A topographic GCC map is generated from one horizontal line scan followed by 15 vertical line scans(7 mm in length and at a 0.5 mm interval) centered 1 mm temporal to the fovea. GCC thickness was determined as the combined thickness of the RNFL, ganglion cell layer and inner plexiform layer. The pattern-based parameters focal loss volume (FLV) and global loss volume (GLV) were measured. Retinal macular thickness measured by Retina Map Scan centered at the fovea. Only scans with signal strength >65 were analyzed.
Results:
Central foveal thickness failed to show statistically significant difference between normal and diabetes group although it was significant among glaucoma and diabetes patients. Macular thickness in parafoveal and perifoveal area showed no significant difference in Normal and Diabetes group, and Glaucoma and Both (glaucoma + diabetes) group when hemispherical areas and sectors were compared. Ganglion cell complex (Total, superior, inferior) showed that there was no significant difference between Normal and Diabetes group, and between Glaucoma and Both group (except in average superior GCC).
Conclusions:
Diabetes does not affect GCC and macular thickness parameters significantly when compared to Normal patients. Diabetes does not act as a confounding factor for total macular thickness parameters in glaucoma patients. Definite role of Diabetes in GCC parameters in glaucoma patients remains inconclusive.
Financial Disclosure:
None
